In summary, though the driver and passenger mutations that drive leukemogenesis in AML are still being defined, the genes impacted by genetic lesions or mutations have been mapped primarily to signaling molecules, transcription factors or epigenetic genes (e.g., FLT3, Ras, AML1, C/EBPa, IDH1, IDH2, DNMT3A, PU.1) and those effected by chromosomal rearrangements are primarily mapped to transcription factors of relevance in hematopoiesis (e.g., PML-RARa, PLZF-RARa, CEBPa-MYH11, AML-ETO [RUNX1T1-RUNX1]). The gene discussed is IDH2; the disease is acute myeloid leukemia.